SCHEMBL6664403

SCHEMBL6664403

CC1(O)CCCC1Oc1ncc(C(F)(F)F)cc1-c1cccc(S(N)(=O)=O)c1

nearest known ligand 0.72

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 8/20 0.72
PTGS1 P23219 2/20 0.45
IKBKB O14920 1/20 0.39
CHUK O15111 1/20 0.39
SCN10A Q9Y5Y9 8/20 0.38
NR1I2 O75469 1/20 0.38
CACNA1C Q13936 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
SYK P43405 1/20 0.37
CCNK O75909 1/20 0.36
CDK7 P50613 1/20 0.36
CCNH P51946 1/20 0.36
MNAT1 P51948 1/20 0.36
CDK12 Q9NYV4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6660279 0.92 PTGS2 (0.82) PTGS2PTGS1PTGDR2SYK
SCHEMBL6661056 0.90 PTGS2 (0.84) PTGS2PTGS1IKBKB
SCHEMBL6659481 0.90 PTGS2 (0.77) PTGS2PTGS1PTGDR2SYK
SCHEMBL6659905 0.84 PTGS2 (1.00) PTGS2PTGS1PTGDR2
SCHEMBL6661828 0.84 PTGS2 (1.00) PTGS2PTGS1PTGDR2
SCHEMBL6659480 0.81 PTGS2 (0.94) PTGS2PTGS1PTGDR2
SCHEMBL6658493 0.81 PTGS2 (0.65) PTGS2PTGS1PTGDR2
SCHEMBL6662836 0.78 PTGS2 (0.61) PTGS2PTGS1
SCHEMBL6666781 0.76 PTGS2 (0.61) PTGS2PTGS1
SCHEMBL6666778 0.76 PTGS2 (0.61) PTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1012142-B1 2,3,5-TRISUBSTITUTED PYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2 MERCK FROSST CANADA INC (CA) 2004-08-11 EP claimed
EP-1012142-A1 2,3,5-TRISUBSTITUTED PYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2 Merck Frosst Canada & Co. (CA) 2000-06-28 EP claimed
US-6046217-A TREATING AN INFLAMMATORY DISEASE SUSCEPTIBLE TO TREATMENT WITH A NON-STEROIDAL ANTI-INFLAMMATORY AGENT COMPRISING ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT A NONTOXIC 3-PHENYL SUBSTITUTED PYRIDINES MERCK FROSST CANADA & CO. (CA) 2000-04-04 US claimed
WO-1999014194-A1 2,3,5-TRISUBSTITUTED PYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2 MERCK FROSST CANADA & CO. (CA) 1999-03-25 WO claimed
EP-1012142-B1 2,3,5-TRISUBSTITUTED PYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2 MERCK FROSST CANADA INC (CA) 2004-08-11 EP disclosed
EP-1012142-A1 2,3,5-TRISUBSTITUTED PYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2 Merck Frosst Canada & Co. (CA) 2000-06-28 EP disclosed
US-6046217-A TREATING AN INFLAMMATORY DISEASE SUSCEPTIBLE TO TREATMENT WITH A NON-STEROIDAL ANTI-INFLAMMATORY AGENT COMPRISING ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT A NONTOXIC 3-PHENYL SUBSTITUTED PYRIDINES MERCK FROSST CANADA & CO. (CA) 2000-04-04 US disclosed
WO-1999014194-A1 2,3,5-TRISUBSTITUTED PYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2 MERCK FROSST CANADA & CO. (CA) 1999-03-25 WO disclosed